Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Flecainide/modafinil (Primary)
- Indications Sleep disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Theranexus
- 16 Jul 2018 According to a Theranexus media release, results are expected by the end of first half of 2019.
- 16 Jul 2018 Status changed from planning to recruiting, according to an Theranexus media release.
- 16 Jul 2018 According to an Theranexus media release, first patient has been included in this trial.